ERBB2 and serous adenocarcinoma: A randomized clinical trial that began in 2011 and is currently in phase II (NCT01367002) is investigating the therapeutic response of stage III or IV or recurrent serous carcinomas to carboplatin/paclitaxel compared to carboplatin/paclitaxel to which trastuzumab, an anti-HER2 agent, is added [22].